| Title |
Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma
|
|---|---|
| Published in |
Cancer Research Communications, January 2022
|
| DOI | 10.1158/2767-9764.crc-21-0088 |
| Pubmed ID | |
| Authors |
Lucas A. Salas, Thomas G. Stewart, Bret C. Mobley, Chengwei Peng, Jing Liu, Sudan N. Loganathan, Jialiang Wang, Yanjun Ma, Mitchel S. Berger, Devin Absher, Yang Hu, Paul L. Moots, Brock C. Christensen, Stephen W. Clark |
Twitter Demographics
The data shown below were collected from the profiles of 29 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 12 | 41% |
| Turkey | 1 | 3% |
| United Kingdom | 1 | 3% |
| Unknown | 15 | 52% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 19 | 66% |
| Scientists | 7 | 24% |
| Practitioners (doctors, other healthcare professionals) | 2 | 7% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 14% |
| Unknown | 6 | 86% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 29% |
| Unspecified | 1 | 14% |
| Professor | 1 | 14% |
| Researcher | 1 | 14% |
| Student > Master | 1 | 14% |
| Other | 0 | 0% |
| Unknown | 1 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 2 | 29% |
| Unspecified | 1 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 14% |
| Immunology and Microbiology | 1 | 14% |
| Biochemistry, Genetics and Molecular Biology | 1 | 14% |
| Other | 0 | 0% |
| Unknown | 1 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 118. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 July 2023.
All research outputs
#329,753
of 24,241,559 outputs
Outputs from Cancer Research Communications
#5
of 281 outputs
Outputs of similar age
#9,077
of 508,755 outputs
Outputs of similar age from Cancer Research Communications
#2
of 17 outputs
Altmetric has tracked 24,241,559 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 281 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 508,755 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.